Abstract��Hydroxyethyl starches(HES) are modified natural polymer of amylopectin with volume expansion properties. It has been widely used in the treatment for prevention of hypovolemia and acute normovolemic hemodilution(ANH). However, the potential threats to kidney and coagulation have attracted much attention and controversy in recent years. This review will focus on the specification development and quality study of HES. The article will mainly talk about some quality control items: molecular weight (Mw) and molecular weight distribution, degree of hydroxyethyl (molar substitution, MS), the specific sites of hydroxyethylation (C2/C6 ratio) and assay, all of those are based on the domestic enterprise standards and Europe Pharmacopoeia(EP), and we will combine with the experimental data to give some suggestions on these items quality control. Hopefully to provide some ideas for improving and unifying the quality standard of hydroxyethyl starches.
������,����,���ۺ�. ���һ���������о���չ[J]. �й�ҩѧ��־, 2018, 53(13): 1047-1051.
ZHAO Xiang-mei, WANG Yue, FAN Hui-hong. Overview of the Quality Study on Hydroxyethyl Starches. Chinese Pharmaceutical Journal, 2018, 53(13): 1047-1051.
JOACHIM B, ANDREAS L, FRANK L, et al. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass[J]. J Cardioth Vascul Anesth, 2000, 14(3):264-268.
[2]
JOACHIM B. PRO:hydroxyethyl starch can be safely used in the intensive care patient-the renal debate[J].Intensive Care Med, 2009, 35(8):1331-1336.
[3]
MCLLROY D, KHARASCH E. Acute intravascular volume expansion with rapidly administered crystalloid and colloid in the setting of moderate hypovolemia[J]. Anesth Analg, 2003, 96(6):1572-1577.
[4]
WU Z H. Modern concept of fluid replacement in the surgical patients[J]. J Surg Concept Pract(���������ʵ��), 2004, 9(4):343-344.
[5]
SCHORTGEN F, DEYE N, BROCHARD L. Prefered plasma volume expanders for critically ill payients:results of an international survey[J]. Intensive Care Med, 2004, 30(12):2222-2229.
[6]
WU C S, WU T. The research progress of HES130/0.4[J]. Chin J New Drugs(�й���ҩ��־), 2005, 14(8):981-984.
[7]
ZHANG L. Analysis of the production and marketing of hydroxyethyl starch[J]. Chin Pharm Inf(�й���ҩ��Ϣ), 2015, 35(1):24-29.
[8]
CORNELIUS J, THOMAS A N. Pharmacokinetics of hydroxyethyl starch[J]. Clin Pharmacokinet, 2005, 44(7):681-699.
[9]
KUZMINA N E, MOISEEV S V, KRYLOV V I, et al. Validation of a method for measuring the molar substitution of hydroxythyl starch by 1H-NMR spectroscopy[J].Pharm Chem J, 2016, 50(4):265-269.
[10]
MARTIN W, MICHAEL F M J, SIBYLLE K L, et al. Hydroxyethyl starches:different products-different effects[J]. Anesthesiol, 2009, 111(1):187-202.
[11]
ZHOU X, ZHANG X L. The clinical studies of hydroxyethyl starchesa plasma volume expander [J].Chin Pharm J(�й�ҩѧ��־), 2007, 42(9):646-649.
[12]
JOACHIM B, HAISCH G, SUTTNER S, et al. Effects of a new modified, balanced hydroxyethyl starch preparation(Hextend) on measures of coagulation[J].Br J Anaesth, 2002, 89(5):722-728.
[13]
MAHLON M W, ROBERTA J N, WILLIAM J S. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a Meta-analysis of postoperative bleeding[J].Ann Thorac Surg, 2001, 72(2):527-534.
[14]
TREIB J, BARON J F, GRAUER M T, et al. An international view of hydroxyethyl starches[J].Intensive Care Med, 1999, 25(3):258-268.
[15]
SIBYLLE A K L, CORNELIUS J, WILHELM S, et al. The effects of hydroxyethyl starch 130/0.4(6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials[J].Anesth Analg, 2008, 107(2):382-390.
[16]
LEHMANN G, MARX G, FORSTER H. Bioequivalence comparison between hydroxyethyl starch 130/0.42/6:1 and hydroxyethyl starch 130/0.4/9:1[J].Drugs Res Develop, 2007, 8(4):229-240.
[17]
CFDA. Hydroxyethyl starch 40/20 sodium chloride injection and renal function damage(���һ����40��20�Ȼ���ע��Һ����������)[ES/OL].(2005-04-12). http://www.sda.gov.cn/WS01/CL0078/11280.html.
[18]
FRANZISKA S, JANAINA O, FABIO T, et al. Effects of a predominantly hydroxyethyl starch(HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients[J].Intensive Care Med, 2009, 35(9):1539-1547.
[19]
ROTEN I, MADJBPOUR C, FRASCAROLO P, et al. Molar substitution and C2/C6 ratio of hydroxyethyl starch:influence on blood coagulation[J].Br J Anaesth, 2006, 96(4):455-463.
[20]
EMA. Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients[ES/OL].(2013.10.23) http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Hydroxyethyl_starch-containing_solutions/human_referral_prac_000012.jsp&mid=WC0b01ac05805c516f.
[21]
CFDA. The state administration of food and drug administration has warned about the safety risks of hydroxyethyl starch(����ʳƷҩƷ�ල�����ܾ����ѹ�ע�����һ������ҩƷ��ȫ����)[ES/OL].(2014-02-26). http://www.sfda.gov.cn/WS01/CL0051/97074.html
[22]
EMA. PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market[ES/OL].(2018-01-12). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/01/news_detail_002882.jsp&mid=WC0b01ac058004d5c1
[23]
EMA. Hydroxyethyl-starch solutions for infusion to be suspended-CMDh endorses PRAC recommendation[ES/OL].(2018-01-26). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/01/news_detail_002892.jsp&mid=WC0b01ac058004d5c1
[24]
EMA. PRAC to further consider unmet medical needs for hydroxyethyl-starch (HES) solutions for infusion[ES/OL].(2018-04-13). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/04/news_detail_002938.jsp&mid=WC0b01ac058004d5c1.
[25]
ROMUALD B, CLEMENS F, CHRISTIAN J W. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch[J].Clin Pharm, 2012, 51(4):225-236.
[26]
FAN H H, LI J. Determination of molecular weight and molecular weight distribution of polysaccharides[Z].National Institutes for Food and Drug Control(�й�ʳƷҩƷ�춨�о�Ժ), 2000.
[27]
SHI L H. Gel Chromatography(����ɫ��)[M]. Beijing:Science Press, 1980.
[28]
STEPHEN E H, GARY G A, RICHARD B G. Molecular weight analysis of starches: which technique?[J]. Starch/St rke, 2016, 68(9-10):846-853.
[29]
EP7.0 Vol ��(2010)[S].2010:2984-2988.
[30]
YING C L, DAVID M B, JAMES E C. Determination of the molar substitution of hydroxyethyl starches by gas chromatography[J]. Anal Chem, 1983, 55(2):334-338.
[31]
The People′s Republic of China Ministry of Health Pharmaceutical Standards Volume �� sixth (1998)(1988���л�����ҩƷ����������������ҩƷ��һ�ֲ�)[S].1998:125.
[32]
YOSHIDA M, YAMASHITA T, MATSUO J, et al.Enzymic degradation of hydroxuethyl starch:Part ��.Influence of the distribution of hydroxyethyl groups on the enzymic degradation of hydroxyethyl starch[J].St rke, 1973, 25(11):373-376.
[33]
DU L W, HUANG Z P, YANG H Y, et al. The assaying of hydroxyethyl starch 200/0.5 using polarimetry[J].Pract Pharm Clin Rem(ʵ��ҩ�����ٴ�), 2009, 12(1):35.
[34]
XV D Q, BO Y M, ZHANG Z C. Study on the method of measuring the content of hydroxyethyl starch[J]. J Mudanjiang Med Coll(ĵ����ҽѧԺѧ��), 1994, 15(3):8-9.
2018, Vol. 53 
